Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,054 people get FRX articles and Market Currents by email alert.
Get email alerts on FRX »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
Earnings Preview: Forest LaboratoriesVytautas Drumelis • Tue, Jul 10, 2012 -
Investors Can Still Benefit From Street's Doubts About Forest LabsStephen Simpson • Tue, Apr 17, 2012
-
-
-
-
Forest Laboratories Misses Despite Increased RevenuesZacks Investment Research • Wed, Oct 19, 2011 -
Forest Labs Earnings PreviewZacks Investment Research • Fri, Oct 14, 2011
-
Forest Labs Is Not The Value Stock It Appears To BeVince Martin • Thu, Sep 1, 2011 -
Feds Will Not Ban Forest CEO From Health ProgramsPharmalot • Mon, Aug 8, 2011 -
-
Forest Labs Earnings PreviewZacks Investment Research • Wed, Jul 13, 2011
-
-
-
-
Earnings Scorecard: Forest LabsZacks Investment Research • Mon, Jan 31, 2011
-
To learn more about Seeking Alpha Pro, click here.
-
Can Cempra Beat The Superbugs?C.R. Jackson • Mon, Jun 17 -
-
-
-
-
-
-
-
-
-
-
-
Lundbeck Could Cheer Up Patient InvestorsStephen Simpson • Wed, Feb 13
-
-
-
-
-
-
-
For NovaBay, Simplicity Is The Father Of InventionRyan's View • Mon, Nov 12, 2012
-
Forest Laboratories F1Q11 (Qtr End 6/30/10) Earnings Call TranscriptTue, Jul 20, 2010
-
Forest Laboratories, Inc Q1 2009 Earnings Call TranscriptTue, Apr 21, 2009
-
Business Wire (Thu, 8:00AM)
-
Business Wire (Tue, 8:00AM)
-
at MarketWatch.com (May 23, 2013)
-
Business Wire (May 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 20, 2013)
-
at CNBC.com (Apr 16, 2013)
-
Business Wire (Apr 2, 2013)
-
Business Wire (Jan 17, 2013)
-
at Fox Business (Jan 15, 2013)
-
at MarketWatch.com (Jan 15, 2013)
-
at MarketWatch.com (Jan 15, 2013)
-
at CNBC.com (Jan 15, 2013)
-
Business Wire (Jan 15, 2013)
FRX vs. ETF Alternatives
Company Description
BUSINESS: General
Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products which require a physician's prescription. Our most important United States products consist of branded ethical drug specialties marketed... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, June 11, 9:54 AM Peace finally breaks out at Forest Laboratories (FRX -2.2%) as the company appoints Carl Icahn nominee Vincent Intrieri as an independent director. In return, Icahn, who owns almost 12% in the company, has agreed to vote for Forest's slate of 11 board nominees at the firm's upcoming annual meeting, thereby avoiding a third successive proxy battle. Intrieri will join the committee charged with finding a successor to retiring CEO Howard Solomon. (PR) Comment! [Healthcare]
- Friday, June 7, 7:38 AM Forest Laboratories (FRX) may be unable to avoid a third proxy battle in as many years with an interminably dissatisfied Carl Icahn, sources tell Reuters. The company has engaged the billionaire investor — who holds a near 12% stake in the company — throughout the year but with the deadline to file a slate of alternative directors less than two weeks away, "there is no guarantee of an amicable settlement." Comment! [Healthcare]
- Thursday, May 23, 8:19 AM Forest Labs (FRX) expects to name a successor to Howard Solomon by the end of the year as the CEO announces his retirement, effective Dec. 31 (he'll be 86). Solomon expects to remain Chairman through the 2014 annual meeting, at which a new one will be elected. (PR) Comment! [Healthcare]
- Wednesday, May 1, 4:31 PM Forest Laboratories (FRX) and Almirall announce positive topline results from a second six-month Phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair inhaler. Results showed the combination demonstrated statistically significant improvements in change from baseline for the co-primary endpoints. Comment! [Healthcare, Global & FX]
- Tuesday, April 23, 8:30 AM Ironwood Pharmaceuticals (IRWD) sinks 13.3% premarket after saying sales of Linzess — the IBS drug the company markets with Forest Labs (FRX) — were $4.5M for Q1 versus expectations of $11-13M. Credit Suisse and Wedbush previously said early evidence suggested demand for the drug was strong. Irina Rivkind at Cantor says Synergy's (SGYP) investigational candidate plecanatide has the potential to achieve revenue parity with Linzess. Comment! [On the Move, Healthcare]
- Tuesday, April 23, 7:05 AM Forest Labs (FRX): FQ4 EPS of $0.25 beats by $0.09. Revenue of $783.2M (-21.4% Y/Y) misses by $23.8M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, April 23, 12:05 AM Notable earnings before Tuesday’s open: ACI, AKS, AOS, APD, ARMH, CIT, CNC, COH, DAL, DD, DFS, EAT, ECA, FMER, FRX, GCI, GNTX, IDXX, IIVI, IR, IRWD, ITW, JCI, JNS, LCC, LECO, LMT, LXK, MOLX, PCAR, PCH, PII, PMT, PNR, R, RAI, RF, RSH, SNV, ST, TRV, UTX, WAT, XRX 1 Comment [Earnings]
- Monday, April 22, 5:30 PM Notable earnings before Tuesday’s open: ACI, AKS, AOS, APD, ARMH, CIT, CNC, COH, DAL, DD, DFS, EAT, ECA, FMER, FRX, GCI, GNTX, IDXX, IIVI, IR, IRWD, ITW, JCI, JNS, LCC, LECO, LMT, LXK, MOLX, PCAR, PCH, PII, PMT, PNR, R, RAI, RF, RSH, SNV, ST, TRV, UTX, WAT, XRX Comment! [Earnings]
- Tuesday, April 16, 7:17 AM Carl Ichan-backed Forest Laboratories (FRX) and Almirall say a combination COPD treatment of aclidinium and formoterol met both endpoints in a Phase III clinical trial. Data from a second Phase III trial is forthcoming and, if positive, the companies expect to file an NDA with the FDA. Comment! [Healthcare]
- Tuesday, April 9, 11:44 AM Synergy Pharmaceuticals (SGYP +10.3%) soars on heavy volume after Cantor Fitzgerald raises its price target on the shares to $15 from $12. Irina Rivkind says the company's lead investigational drug plecanatide can "achieve revenue parity" with Ironwood (IRWD -0.5%) and Forest Laboratories' (FRX -0.2%) Linzess, an FDA approved treatment for constipation. Comment! [Healthcare, On the Move]
- Tuesday, February 12, 3:33 PM AstraZeneca Plc (AZN) needs to make a big buy to reverse its slide, recommends a number of Wall Street analysts, saying the drugmaker needs a "transformational deal" to return it to profit growth. A deal for Shire (SHPG +0.2%) or Forest Labs (FRX +0.7%) would rival its's $15B acquisition of MedImmune in 2007. SHPG could help fill the gap with patent-protected medicines for rare diseases and leading ADD therapies, says Kepler Capital Markets, while FRX's lung treatment would bolster the company's respiratory business. Comment! [Healthcare, M&A]
- Tuesday, January 15, 12:47 PM Ironwood Pharmaceuticals (IRWD +1%) gives a Q4 business update on the commercial launch of its irritable bowel syndrome Linzess in the U.S., saying its partner, Forest Laboratories (FRX) reported Q4 product sales of $19.2M. The company also said another commercial partner, Almirall, received approval for Constella for the treatment of moderate to severe irritable bowel syndrome in the European Union. Commercial launch will be initiated in the first half of FY13. Comment! [Healthcare, On the Move]
- Tuesday, January 15, 8:13 AM More on Forest Laboratories (FRX -5%) FQ3: swings to net loss of $153.6M from profit of $278.4M, with earnings hurt by the expiration of Lexapro's patent in March 2012 and upfront licensing payments of $76M. Expects FY 2013 EPS at lower end of forecast of $0.45-$0.60 vs consensus of $0.25 - which looks to be a substantial discrepancy - and revenue of $3.1-$3.2B vs $3.15B. (PR) Comment! [Earnings, Healthcare, On the Move]
- Tuesday, January 15, 7:03 AM Forest Laboratories (FRX): FQ3 EPS of -$0.21 misses by $0.07. Revenue of $722.7M (-40.2% Y/Y) misses by $38M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, January 15, 12:05 AM Notable earnings before Tuesday’s open: FRX, LEN Comment! [Earnings]
- Monday, January 14, 5:30 PM Notable earnings before Tuesday’s open: FRX, LEN Comment! [Earnings]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.